135 related articles for article (PubMed ID: 29452742)
1. To switch from Botox to Dysport in children with CP, a real world, dose conversion, cost-effectiveness study.
Tedroff K; Befrits G; Tedroff CJ; Gantelius S
Eur J Paediatr Neurol; 2018 May; 22(3):412-418. PubMed ID: 29452742
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of botulinum toxin type A products for the treatment of cervical dystonia.
Kazerooni R; Broadhead C
Am J Health Syst Pharm; 2015 Feb; 72(4):301-7. PubMed ID: 25631837
[TBL] [Abstract][Full Text] [Related]
3. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin type A in the management of equinus in children with cerebral palsy: an evidence-based economic evaluation.
Houltram J; Noble I; Boyd RN; Corry I; Flett P; Graham HK
Eur J Neurol; 2001 Nov; 8 Suppl 5():194-202. PubMed ID: 11851748
[TBL] [Abstract][Full Text] [Related]
5. A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis.
Simonetta Moreau M; Cauhepe C; Magues JP; Senard JM
Br J Dermatol; 2003 Nov; 149(5):1041-5. PubMed ID: 14632812
[TBL] [Abstract][Full Text] [Related]
6. Same-patient prospective comparison of Botox versus Dysport for the treatment of primary axillary hyperhidrosis and review of literature.
Vergilis-Kalner IJ
J Drugs Dermatol; 2011 Sep; 10(9):1013-5. PubMed ID: 22052270
[TBL] [Abstract][Full Text] [Related]
7. Development of an inventory of goals using the International Classification of Functioning, Disability and Health in a population of non-ambulatory children and adolescents with cerebral palsy treated with botulinum toxin A.
Nguyen L; Mesterman R; Gorter JW
BMC Pediatr; 2018 Jan; 18(1):1. PubMed ID: 29301539
[TBL] [Abstract][Full Text] [Related]
8. Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs.
Bentivoglio AR; Fasano A; Ialongo T; Soleti F; Lo Fermo S; Albanese A
Neurotox Res; 2009 Apr; 15(3):224-31. PubMed ID: 19384595
[TBL] [Abstract][Full Text] [Related]
9. Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm.
Bentivoglio AR; Fasano A; Ialongo T; Soleti F; Lo Fermo S; Albanese A
Eur J Neurol; 2009 Mar; 16(3):392-8. PubMed ID: 19364366
[TBL] [Abstract][Full Text] [Related]
10. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A--Dysport and Botox--assuming a ratio of 4:1.
Sampaio C; Ferreira JJ; Simões F; Rosas MJ; Magalhães M; Correia AP; Bastos-Lima A; Martins R; Castro-Caldas A
Mov Disord; 1997 Nov; 12(6):1013-8. PubMed ID: 9399229
[TBL] [Abstract][Full Text] [Related]
11. [Cost analysis of the use of botulinum toxin type A in Spain].
de Andrés-Nogales F; Morell A; Aracil J; Torres C; Oyagüez I; Casado MA
Farm Hosp; 2014 May; 38(3):193-201. PubMed ID: 24951903
[TBL] [Abstract][Full Text] [Related]
12. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm.
Nüssgens Z; Roggenkämper P
Graefes Arch Clin Exp Ophthalmol; 1997 Apr; 235(4):197-9. PubMed ID: 9143885
[TBL] [Abstract][Full Text] [Related]
13. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
Wissel J; Entner T
Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
[TBL] [Abstract][Full Text] [Related]
14. A Comparison of Botox 100 U/mL and Dysport 100 U/mL Using Dose Conversion Ratio 1: 3 and 1: 1.7 in the Treatment of Cervical Dystonia: A Double-Blind, Randomized, Crossover Trial.
Rystedt A; Zetterberg L; Burman J; Nyholm D; Johansson A
Clin Neuropharmacol; 2015; 38(5):170-6. PubMed ID: 26366966
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of botulinum toxin: differences between type A preparations.
Rosales RL; Bigalke H; Dressler D
Eur J Neurol; 2006 Feb; 13 Suppl 1():2-10. PubMed ID: 16417591
[TBL] [Abstract][Full Text] [Related]
16. Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.
Badarny S; Susel Z; Honigman S
Isr Med Assoc J; 2008 Jul; 10(7):520-2. PubMed ID: 18751631
[TBL] [Abstract][Full Text] [Related]
17. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia.
Odergren T; Hjaltason H; Kaakkola S; Solders G; Hanko J; Fehling C; Marttila RJ; Lundh H; Gedin S; Westergren I; Richardson A; Dott C; Cohen H
J Neurol Neurosurg Psychiatry; 1998 Jan; 64(1):6-12. PubMed ID: 9436720
[TBL] [Abstract][Full Text] [Related]
18. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study.
Marchetti A; Magar R; Findley L; Larsen JP; Pirtosek Z; Růzicka E; Jech R; Sławek J; Ahmed F
Mov Disord; 2005 Aug; 20(8):937-44. PubMed ID: 15810022
[TBL] [Abstract][Full Text] [Related]
19. Cost-minimization analysis in the treatment of spasticity in children with cerebral palsy with botulinum toxin type A: an observational, longitudinal, retrospective study.
Tapias G; García-Romero M; Crespo C; Cuesta M; Forné C; Pascual-Pascual SI
Farm Hosp; 2016 Sep; 40(5):412-26. PubMed ID: 27570991
[TBL] [Abstract][Full Text] [Related]
20. Value of botulinum toxin injections preceding a comprehensive rehabilitation period for children with spastic cerebral palsy: A cost-effectiveness study.
Schasfoort F; Dallmeijer A; Pangalila R; Catsman C; Stam H; Becher J; Steyerberg E; Polinder S; Bussmann J
J Rehabil Med; 2018 Jan; 50(1):22-29. PubMed ID: 28949368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
